Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
World J Surg. 2024 Jan;48(1):110-120. doi: 10.1002/wjs.12014. Epub 2023 Dec 12.
Adrenocortical carcinoma (ACC) is a notoriously aggressive cancer with a dismal prognosis, especially for patients with metastatic disease. Metastatic ACC is classically a contraindication to operative management. Here, we evaluate the impact of primary tumor resection and metastasectomy on survival in metastatic ACC.
We performed a retrospective cohort study of patients with metastatic ACC (2010-2019) utilizing the National Cancer Database. The primary outcome was overall survival (OS). Cox proportional hazards models were developed to evaluate the associations between surgical management and survival. Propensity score matching (PSM) was utilized to account for selection bias in receipt of surgery.
Of 976 subjects with metastatic ACC, 38% underwent surgical management. Median OS across all patients was 7.6 months. On multivariable Cox proportional hazards regression, primary tumor resection alone (HR: 0.523; p<0.001) and primary resection with metastasectomy (HR: 0.372; p<0.001) were significantly associated with improved OS. Metastasectomy alone had no association with OS (HR: 0.909; p=0.740). Primary resection with metastasectomy was associated with improved OS over resection of the primary tumor alone (HR: 0.636; p=0.018). After PSM, resection of the primary tumor alone remained associated with improved OS (HR 0.593; p<0.001), and metastasectomy alone had no survival benefit (HR 0.709; p=0.196) compared with non-operative management; combined resection was associated with improved OS over primary tumor resection alone (HR 0.575, p=0.008).
In metastatic ACC, patients may benefit from primary tumor resection alone or in combination with metastasectomy, however further research is required to facilitate appropriate patient selection.
肾上腺皮质癌(ACC)是一种众所周知的侵袭性癌症,预后极差,尤其是对于转移性疾病的患者。转移性 ACC 经典地被认为是手术治疗的禁忌证。在这里,我们评估了原发性肿瘤切除术和转移灶切除术对转移性 ACC 患者生存的影响。
我们使用国家癌症数据库对 2010-2019 年转移性 ACC 患者进行了回顾性队列研究。主要结局是总生存(OS)。采用 Cox 比例风险模型评估手术管理与生存之间的关联。利用倾向评分匹配(PSM)来解释手术治疗选择偏倚。
在 976 例转移性 ACC 患者中,38%接受了手术治疗。所有患者的中位 OS 为 7.6 个月。在多变量 Cox 比例风险回归中,单独进行原发性肿瘤切除术(HR:0.523;p<0.001)和同时进行原发性肿瘤切除术和转移灶切除术(HR:0.372;p<0.001)与 OS 改善显著相关。单独进行转移灶切除术与 OS 无相关性(HR:0.909;p=0.740)。同时进行原发性肿瘤切除术和转移灶切除术与单独进行原发性肿瘤切除术相比,OS 得到改善(HR:0.636;p=0.018)。PSM 后,单独进行原发性肿瘤切除术仍与 OS 改善相关(HR 0.593;p<0.001),而单独进行转移灶切除术对生存没有益处(HR 0.709;p=0.196),与非手术治疗相比;联合切除术与单独进行原发性肿瘤切除术相比,OS 得到改善(HR 0.575,p=0.008)。
在转移性 ACC 中,患者可能从单独进行原发性肿瘤切除术或联合进行原发性肿瘤切除术和转移灶切除术获益,但需要进一步研究来促进适当的患者选择。